P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

Authors :: V. Gupta
A. Yacoub
S. Verstovsek
R. A. Mesa
C. N. Harrison
G. Barosi
J.-J. Kiladjian
H. J. Deeg
S. Fazal
L. Foltz
R. J. Mattison
C. B. Miller
V. Parameswaran
C. Hernandez
J. Zhang
M. Talpaz
Source :: HemaSphere. 6:932-933
Publication Year :: 2022
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2022.

Full Text Access

Tools